<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00654901</url>
  </required_header>
  <id_info>
    <org_study_id>A3L21</org_study_id>
    <nct_id>NCT00654901</nct_id>
  </id_info>
  <brief_title>Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™</brief_title>
  <official_title>Immunogenicity Study of the Antibody Persistence and Booster Effect of the DTaP-IPV-Hep B-PRP~T Combined Vaccine at 15 to 18 Months of Age Following a Primary Series of DTaP-IPV-Hep B-PRP~T or Infanrix Hexa™ Administered at 2, 4, and 6 Months of Age in Healthy Mexican Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a follow-up of Study A3L11 (NCT00404651).

      Immunogenicity

        -  To describe the antibody persistence following a primary series vaccination of either
           DTaP-IPV-Hep B-PRP~T or Infanrix hexa™.

        -  To describe the immunogenicity of a booster dose of DTaP-IPV-HepB-PRP~T in a subset of
           subjects.

      Safety

      - To describe the safety profile after a booster dose of DTacP-IPV-HepB-PRP~T.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers of Antibodies Before and After Booster Vaccination With DTaP-IPV-Hep B-PRP~T</measure>
    <time_frame>Day 0 (pre-booster) and Day 30 (one month post-booster)</time_frame>
    <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for diphtheria by toxin neutralization test, and for tetanus by enzyme linked immunosorbent assay (ELISA). Antibody titers were measured for poliovirus types 1, 2, and 3 by neutralization assay. Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by ELISA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Antibody Persistence Before and Immunogenicity Response After Booster Vaccination With DTaP-IPV-Hep B-PRP~T Vaccine</measure>
    <time_frame>Day 0 (pre-booster) and Day 30 (one month post-booster)</time_frame>
    <description>Antibody persistence and immunogenicity response:
Level 1: ≥ 10 mIU/mL for hepatitis B (Hep B), ≥ 0.15 µg/mL for Haemophilus influenzae type b (PRP), and ≥ 0.01 IU/mL for diphtheria (D) and tetanus (T). Level 2: ≥ 100 mIU/mL (Hep B), ≥ 1.0 µg/mL (PRP), and ≥ 0.1 IU/mL (D and T) Level 3, ≥ 1.0 IU/mL (D and T). Anti-polio titers were defined as ≥ 8 (1.dil), and pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by a 4 fold increase from Day 0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Injection Site or Systemic Reactions After Vaccination With DTaP-IPV-Hep B-PRP~T Vaccine</measure>
    <time_frame>Days 0 up to 7 after any injection</time_frame>
    <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling, Extensive Swelling of Vaccinated Limb. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Grade 3 reactions were defined as: Pain, cries when injected limb is moved or movement of injected limb reduced; Erythema and swelling, ≥ 5cm; Extensive swelling of limb; Pyrexia, ≥ 39.6ºC; Vomiting ≥ 6 episodes/24 hours or requiring parenteral hydration; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ feeds or most feeds; Irritability, inconsolable.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">881</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Hepatitis B</condition>
  <condition>Poliomyelitis</condition>
  <condition>Haemophilus Influenzae Type B Infection</condition>
  <arm_group>
    <arm_group_label>DTaP-IPV-Hep B-PRP~T Batch 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651); and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTaP-IPV-Hep B-PRP~T Batch 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DTaP-IPV-Hep B-PRP~T Batch 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 (NCT00404651) and will receive a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infanrix Hexa™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), (Infanrix Hexa™) plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 (NCT00404651) and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>DTaP-IPV-Hep B-PRP~T Batch 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>DTaP-IPV-Hep B-PRP~T Batch 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>DTaP-IPV-Hep B-PRP~T Batch 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix Hexa™</intervention_name>
    <description>0.5 mL, Intramuscular</description>
    <arm_group_label>Infanrix Hexa™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Toddlers previously included in Study A3L11 (NCT00404651) who completed the three-dose
             primary series vaccination of either DTaP-IPV-HepB-PRP-T or Infanrix hexa™ at 2, 4 and
             6 months of age

          -  Toddlers of 15 to 18 months (456 to 578 days) of age, inclusive

          -  Informed Consent Form signed by at least one parent or legal representative and two
             mandatory witnesses

          -  Able to attend all scheduled visits and to comply with all trial procedures.

        Exclusion Criteria:

          -  Participation in another clinical trial in the 4 weeks preceding the booster
             vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term
             systemic corticosteroid therapy.

          -  Systemic hypersensitivity to any of the vaccine components or history of a life
             threatening reaction to a vaccine containing the same substances.

          -  Chronic illness at a stage that could interfere with trial conduct or completion.

          -  Blood or blood-derived products received in the last 3 months.

          -  Any vaccination in the 4 weeks preceding the booster vaccination.

          -  Any vaccination planned until the next visit.

          -  History of documented pertussis, tetanus, diphtheria, polio, Haemophilus influenzae
             type b or hepatitis B (HB) infection(s) (confirmed either clinically, serologically or
             microbiologically).

          -  Administration of a vaccine against pertussis, tetanus, diphtheria, polio, Hib, and/or
             hepatitis B infection(s) since the end of participation in Study A3L11.

          -  Coagulopathy, thrombocytopenia or a bleeding disorder contraindicating intramuscular
             vaccination.

          -  Known maternal history of human immunodeficiency virus (HIV), Hepatitis B surface
             antigen (HbsAg) or Hepatitis C seropositivity.

          -  Subjects with any related serious adverse event that occurred following the three-dose
             primary series administration of the investigational vaccine or of the reference
             vaccine in Study A3L11.

          -  History of seizures.

          -  Febrile (temperature ≥38.0°C) or acute illness on the day of inclusion

          -  Known contraindication to further vaccination with a pertussis vaccine, i.e.:
             Encephalopathy; Temperature &gt;40.0°C within 48 hours following a vaccine injection, not
             due to another identifiable cause during the primary series; Inconsolable crying that
             occurred for &gt;3 hours within 48 hours following vaccine injection during the primary
             series; Hypotonic hyporesponsive episode within 48 hours following vaccine injection
             during the primary series; Seizures with or without fever within 3 days following
             vaccine injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Months</minimum_age>
    <maximum_age>18 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Estado de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Insurgentes Cuicuilco</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2008</study_first_posted>
  <results_first_submitted>May 6, 2013</results_first_submitted>
  <results_first_submitted_qc>May 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2013</results_first_posted>
  <last_update_submitted>April 8, 2016</last_update_submitted>
  <last_update_submitted_qc>April 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>Invasive Haemophilus influenzae type b.</keyword>
  <keyword>Haemophilus Influenzae Type B Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled from 25 March 2008 to 28 November 2008 at 5 clinical centers in Mexico.</recruitment_details>
      <pre_assignment_details>A total of 881 participants who met the inclusion, but no exclusion criteria were enrolled and vaccinated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DTaP-IPV-Hep B-PRP~T Batch 1</title>
          <description>Participants had received 3 primary doses of Batch 1 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="P2">
          <title>DTaP-IPV-Hep B-PRP~T Batch 2</title>
          <description>Participants had received 3 primary doses of Batch 2 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="P3">
          <title>DTaP-IPV-Hep B-PRP~T Batch 3</title>
          <description>Participants had received 3 primary doses of Batch 3 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="P4">
          <title>Infanrix Hexa™</title>
          <description>Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 and received a booster dose of DTaP-IPV-Hep B-PRP~T at Day 0 in the present study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="262"/>
                <participants group_id="P3" count="252"/>
                <participants group_id="P4" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="262"/>
                <participants group_id="P3" count="250"/>
                <participants group_id="P4" count="113"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DTaP-IPV-Hep B-PRP~T Batch 1</title>
          <description>Participants had received 3 primary doses of Batch A of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="B2">
          <title>DTaP-IPV-Hep B-PRP~T Batch 2</title>
          <description>Participants had received 3 primary doses of Batch B of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="B3">
          <title>DTaP-IPV-Hep B-PRP~T Batch 3</title>
          <description>Participants had received 3 primary doses of Batch 3 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="B4">
          <title>Infanrix Hexa™</title>
          <description>Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]) (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 and received a booster dose of DTaP-IPV-Hep B-PRP~T at Day 0 in the present study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="254"/>
            <count group_id="B2" value="262"/>
            <count group_id="B3" value="252"/>
            <count group_id="B4" value="113"/>
            <count group_id="B5" value="881"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="252"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.3" spread="1.51"/>
                    <measurement group_id="B2" value="17.2" spread="1.47"/>
                    <measurement group_id="B3" value="17.4" spread="1.42"/>
                    <measurement group_id="B4" value="17.1" spread="1.51"/>
                    <measurement group_id="B5" value="17.3" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="443"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="262"/>
                    <measurement group_id="B3" value="252"/>
                    <measurement group_id="B4" value="113"/>
                    <measurement group_id="B5" value="881"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Antibodies Before and After Booster Vaccination With DTaP-IPV-Hep B-PRP~T</title>
        <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for diphtheria by toxin neutralization test, and for tetanus by enzyme linked immunosorbent assay (ELISA). Antibody titers were measured for poliovirus types 1, 2, and 3 by neutralization assay. Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by ELISA.</description>
        <time_frame>Day 0 (pre-booster) and Day 30 (one month post-booster)</time_frame>
        <population>Geometric mean titers were assessed in a subset of participants with endpoint data who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-Hep B-PRP~T Batch 1</title>
            <description>Participants had received 3 primary doses of Batch A of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-Hep B-PRP~T Batch 2</title>
            <description>Participants had received 3 primary doses of Batch B of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-Hep B-PRP~T Batch 3</title>
            <description>Participants had received 3 primary doses of Batch 3 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]) (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 and received a booster dose of DTaP-IPV-Hep B-PRP~T at Day 0 in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Antibodies Before and After Booster Vaccination With DTaP-IPV-Hep B-PRP~T</title>
          <description>Antibody titers were measured for hepatitis B (Hep B) by enhanced chemiluminescence detection, for Haemophilus influenzae type b (PRP) by Farr type radioimmunoassay, for diphtheria by toxin neutralization test, and for tetanus by enzyme linked immunosorbent assay (ELISA). Antibody titers were measured for poliovirus types 1, 2, and 3 by neutralization assay. Antibody titers were measured for pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by ELISA.</description>
          <population>Geometric mean titers were assessed in a subset of participants with endpoint data who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per-Protocol Population).</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti Hep B Pre-booster (N = 58, 60, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.1" lower_limit="56.8" upper_limit="146"/>
                    <measurement group_id="O2" value="127" lower_limit="83.9" upper_limit="193"/>
                    <measurement group_id="O3" value="69.2" lower_limit="42.3" upper_limit="113"/>
                    <measurement group_id="O4" value="127" lower_limit="86.2" upper_limit="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Hep B Post-booster (N = 58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2167" lower_limit="1314" upper_limit="3573"/>
                    <measurement group_id="O2" value="3998" lower_limit="2510" upper_limit="6368"/>
                    <measurement group_id="O3" value="1877" lower_limit="1152" upper_limit="3058"/>
                    <measurement group_id="O4" value="4757" lower_limit="3124" upper_limit="7243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti PRP Pre-booster (N = 58, 60, 57, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.644" upper_limit="1.86"/>
                    <measurement group_id="O2" value="1.32" lower_limit="0.937" upper_limit="1.87"/>
                    <measurement group_id="O3" value="0.880" lower_limit="0.510" upper_limit="1.52"/>
                    <measurement group_id="O4" value="1.33" lower_limit="0.839" upper_limit="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti PRP Post-booster (N = 58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.0" lower_limit="47.4" upper_limit="86.6"/>
                    <measurement group_id="O2" value="94.8" lower_limit="71.6" upper_limit="125"/>
                    <measurement group_id="O3" value="49.7" lower_limit="30.6" upper_limit="80.6"/>
                    <measurement group_id="O4" value="102" lower_limit="72.8" upper_limit="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Diphtheria Pre-booster (N = 58, 60, 57, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.116" lower_limit="0.072" upper_limit="0.187"/>
                    <measurement group_id="O2" value="0.190" lower_limit="0.126" upper_limit="0.287"/>
                    <measurement group_id="O3" value="0.101" lower_limit="0.062" upper_limit="0.164"/>
                    <measurement group_id="O4" value="0.081" lower_limit="0.055" upper_limit="0.119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Diphtheria Post-booster (N = 58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" lower_limit="4.88" upper_limit="12.4"/>
                    <measurement group_id="O2" value="15.2" lower_limit="10.1" upper_limit="23.1"/>
                    <measurement group_id="O3" value="9.31" lower_limit="5.80" upper_limit="14.9"/>
                    <measurement group_id="O4" value="6.01" lower_limit="3.99" upper_limit="9.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Tetanus Pre-booster (N = 58, 60, 57, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.330" lower_limit="0.236" upper_limit="0.462"/>
                    <measurement group_id="O2" value="0.331" lower_limit="0.256" upper_limit="0.427"/>
                    <measurement group_id="O3" value="0.231" lower_limit="0.167" upper_limit="0.318"/>
                    <measurement group_id="O4" value="0.297" lower_limit="0.229" upper_limit="0.385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Tetanus Post-booster (N = 58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.26" lower_limit="3.97" upper_limit="6.96"/>
                    <measurement group_id="O2" value="8.49" lower_limit="6.50" upper_limit="11.1"/>
                    <measurement group_id="O3" value="5.55" lower_limit="4.20" upper_limit="7.33"/>
                    <measurement group_id="O4" value="6.98" lower_limit="5.26" upper_limit="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Polio 1 Pre-booster (N = 57, 59, 57, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="614" lower_limit="382" upper_limit="988"/>
                    <measurement group_id="O2" value="663" lower_limit="458" upper_limit="959"/>
                    <measurement group_id="O3" value="551" lower_limit="356" upper_limit="853"/>
                    <measurement group_id="O4" value="887" lower_limit="571" upper_limit="1378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Polio 1 Post-booster (N = 57, 61, 58, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7037" lower_limit="4977" upper_limit="9949"/>
                    <measurement group_id="O2" value="9938" lower_limit="7418" upper_limit="13313"/>
                    <measurement group_id="O3" value="8907" lower_limit="6474" upper_limit="12254"/>
                    <measurement group_id="O4" value="10173" lower_limit="7909" upper_limit="13086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Polio 2 Pre-booster (N = 58, 59, 56, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="936" lower_limit="584" upper_limit="1501"/>
                    <measurement group_id="O2" value="839" lower_limit="530" upper_limit="1326"/>
                    <measurement group_id="O3" value="531" lower_limit="309" upper_limit="913"/>
                    <measurement group_id="O4" value="1267" lower_limit="747" upper_limit="2152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Polio 2 Post-booster (N = 56, 61, 58, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10756" lower_limit="7636" upper_limit="15151"/>
                    <measurement group_id="O2" value="10224" lower_limit="7476" upper_limit="13981"/>
                    <measurement group_id="O3" value="9232" lower_limit="6549" upper_limit="13014"/>
                    <measurement group_id="O4" value="13482" lower_limit="10245" upper_limit="17742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Polio 3 Pre-booster (N = 58, 59, 56, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428" lower_limit="255" upper_limit="719"/>
                    <measurement group_id="O2" value="373" lower_limit="224" upper_limit="619"/>
                    <measurement group_id="O3" value="241" lower_limit="130" upper_limit="446"/>
                    <measurement group_id="O4" value="896" lower_limit="508" upper_limit="1580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti Polio 3 Post-booster (N = 56, 60, 58, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6597" lower_limit="4281" upper_limit="10164"/>
                    <measurement group_id="O2" value="9575" lower_limit="6859" upper_limit="13365"/>
                    <measurement group_id="O3" value="5296" lower_limit="3503" upper_limit="8007"/>
                    <measurement group_id="O4" value="13337" lower_limit="9619" upper_limit="18491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti PT Pre-booster (N = 57, 59, 55, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="11.6" upper_limit="20.9"/>
                    <measurement group_id="O2" value="14.7" lower_limit="11.8" upper_limit="18.4"/>
                    <measurement group_id="O3" value="14.5" lower_limit="11.3" upper_limit="18.6"/>
                    <measurement group_id="O4" value="15.3" lower_limit="11.6" upper_limit="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti PT Post-booster (N = 58, 61, 58, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186" lower_limit="151" upper_limit="230"/>
                    <measurement group_id="O2" value="200" lower_limit="166" upper_limit="241"/>
                    <measurement group_id="O3" value="171" lower_limit="137" upper_limit="212"/>
                    <measurement group_id="O4" value="162" lower_limit="131" upper_limit="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti FHA Pre-booster (N = 58, 60, 56, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1" lower_limit="30.6" upper_limit="57.9"/>
                    <measurement group_id="O2" value="33.7" lower_limit="26.0" upper_limit="43.8"/>
                    <measurement group_id="O3" value="28.3" lower_limit="21.5" upper_limit="37.3"/>
                    <measurement group_id="O4" value="25.9" lower_limit="19.6" upper_limit="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti FHA Post-booster (N = 58, 60, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410" lower_limit="336" upper_limit="499"/>
                    <measurement group_id="O2" value="455" lower_limit="387" upper_limit="536"/>
                    <measurement group_id="O3" value="346" lower_limit="284" upper_limit="421"/>
                    <measurement group_id="O4" value="291" lower_limit="242" upper_limit="349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Antibody Persistence Before and Immunogenicity Response After Booster Vaccination With DTaP-IPV-Hep B-PRP~T Vaccine</title>
        <description>Antibody persistence and immunogenicity response:
Level 1: ≥ 10 mIU/mL for hepatitis B (Hep B), ≥ 0.15 µg/mL for Haemophilus influenzae type b (PRP), and ≥ 0.01 IU/mL for diphtheria (D) and tetanus (T). Level 2: ≥ 100 mIU/mL (Hep B), ≥ 1.0 µg/mL (PRP), and ≥ 0.1 IU/mL (D and T) Level 3, ≥ 1.0 IU/mL (D and T). Anti-polio titers were defined as ≥ 8 (1.dil), and pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by a 4 fold increase from Day 0.</description>
        <time_frame>Day 0 (pre-booster) and Day 30 (one month post-booster)</time_frame>
        <population>Antibody persistence and immunogenicity response were assessed in all participants with endpoint data who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per Protocol Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-Hep B-PRP~T Batch 1</title>
            <description>Participants had received 3 primary doses of Batch A of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-Hep B-PRP~T Batch 2</title>
            <description>Participants had received 3 primary doses of Batch B of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-Hep B-PRP~T Batch 3</title>
            <description>Participants had received 3 primary doses of Batch 3 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]) (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 and received a booster dose of DTaP-IPV-Hep B-PRP~T at Day 0 in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Antibody Persistence Before and Immunogenicity Response After Booster Vaccination With DTaP-IPV-Hep B-PRP~T Vaccine</title>
          <description>Antibody persistence and immunogenicity response:
Level 1: ≥ 10 mIU/mL for hepatitis B (Hep B), ≥ 0.15 µg/mL for Haemophilus influenzae type b (PRP), and ≥ 0.01 IU/mL for diphtheria (D) and tetanus (T). Level 2: ≥ 100 mIU/mL (Hep B), ≥ 1.0 µg/mL (PRP), and ≥ 0.1 IU/mL (D and T) Level 3, ≥ 1.0 IU/mL (D and T). Anti-polio titers were defined as ≥ 8 (1.dil), and pertussis toxoid (PT) and filamentous hemagglutinin (FHA) by a 4 fold increase from Day 0.</description>
          <population>Antibody persistence and immunogenicity response were assessed in all participants with endpoint data who did not have any protocol deviation that might have interfered with primary criteria evaluation (Per Protocol Population).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-Hep B Level 1 Pre-booster (N=58, 60, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Level 2 Pre-booster (N=58, 60, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Level 1 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Hep B Level 2 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Level 1 Pre-booster (N=58, 60, 57, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Level 2 Pre-booster (N=58, 60, 57, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Level 1 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PRP Level 2 Post booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D Level 1 Pre-booster (N=58, 60, 57, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D Level 2 Pre-booster (N=58, 60, 57, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D Level 1 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D Level 2 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-D Level 3 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T Level 1 Pre-booster (N=58, 60, 57, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T Level 2 Pre-booster (N=58, 60, 57, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T Level 1 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T Level 2 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-T Level 3 Post-booster (N=58, 61, 58, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Pre-booster (N=57, 59, 57, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="57"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 1 Post-booster (N=57, 61, 58, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Pre-booster (N=58, 59, 56, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="56"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 2 Post-booster (N=56, 61, 58, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Pre-booster (N=58, 59, 56, 65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-Polio 3 Post-booster (N=56, 60, 58, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-PT Post-booster (N=57, 59, 55, 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-FHA Post-booster (N=58, 59, 56, 64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Injection Site or Systemic Reactions After Vaccination With DTaP-IPV-Hep B-PRP~T Vaccine</title>
        <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling, Extensive Swelling of Vaccinated Limb. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Grade 3 reactions were defined as: Pain, cries when injected limb is moved or movement of injected limb reduced; Erythema and swelling, ≥ 5cm; Extensive swelling of limb; Pyrexia, ≥ 39.6ºC; Vomiting ≥ 6 episodes/24 hours or requiring parenteral hydration; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ feeds or most feeds; Irritability, inconsolable.</description>
        <time_frame>Days 0 up to 7 after any injection</time_frame>
        <population>Solicited reactions were assessed in all subjects who received at least one dose of vaccine, according to the vaccine actually received (Safety Analysis Population).</population>
        <group_list>
          <group group_id="O1">
            <title>DTaP-IPV-Hep B-PRP~T Batch 1</title>
            <description>Participants had received 3 primary doses of Batch A of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O2">
            <title>DTaP-IPV-Hep B-PRP~T Batch 2</title>
            <description>Participants had received 3 primary doses of Batch B of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O3">
            <title>DTaP-IPV-Hep B-PRP~T Batch 3</title>
            <description>Participants had received 3 primary doses of Batch 3 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
          </group>
          <group group_id="O4">
            <title>Infanrix Hexa™</title>
            <description>Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]) (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 and received a booster dose of DTaP-IPV-Hep B-PRP~T at Day 0 in the present study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection Site or Systemic Reactions After Vaccination With DTaP-IPV-Hep B-PRP~T Vaccine</title>
          <description>Solicited Injection Site Reactions: Pain, Erythema, Swelling, Extensive Swelling of Vaccinated Limb. Solicited Systemic Reactions: Pyrexia (Temperature), Vomiting, Crying, Somnolence, Anorexia, Irritability.
Grade 3 reactions were defined as: Pain, cries when injected limb is moved or movement of injected limb reduced; Erythema and swelling, ≥ 5cm; Extensive swelling of limb; Pyrexia, ≥ 39.6ºC; Vomiting ≥ 6 episodes/24 hours or requiring parenteral hydration; Somnolence, sleeping most of time or difficult to wake up; Anorexia, refuses ≥ feeds or most feeds; Irritability, inconsolable.</description>
          <population>Solicited reactions were assessed in all subjects who received at least one dose of vaccine, according to the vaccine actually received (Safety Analysis Population).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="262"/>
                <count group_id="O3" value="252"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="193"/>
                    <measurement group_id="O3" value="177"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 injection site Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="127"/>
                    <measurement group_id="O3" value="135"/>
                    <measurement group_id="O4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 injection site Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="58"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 injection site Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extensive Swelling of Vaccinated Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Extensive Swelling of Vaccinated Limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="91"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Somnolence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="101"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Anorexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="166"/>
                    <measurement group_id="O4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from Day 0 after the booster injection to up to 6 months post-booster injection.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DTaP-IPV-Hep B-PRP~T Batch 1</title>
          <description>Participants had received 3 primary doses of Batch A of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="E2">
          <title>DTaP-IPV-Hep B-PRP~T Batch 2</title>
          <description>Participants had received 3 primary doses of Batch B of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="E3">
          <title>DTaP-IPV-Hep B-PRP~T Batch 3</title>
          <description>Participants had received 3 primary doses of Batch 3 of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]), and Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed (DTaP-IPV-Hep B-PRP~T) in Study A3L11 and received a booster dose of (DTaP-IPV-Hep B-PRP~T) at Day 0 in the present study.</description>
        </group>
        <group group_id="E4">
          <title>Infanrix Hexa™</title>
          <description>Participants had received 3 primary doses of Diphtheria (D), Tetanus (T), Pertussis (acellular, component [aP]), Hepatitis B (Hep B, [recombinant DNA]) and poliomyelitis (Inactivated [IPV]) (Infanrix hexa™), plus Haemophilus influenzae type b (Hib) conjugated vaccine adsorbed in Study A3L11 and received a booster dose of DTaP-IPV-Hep B-PRP~T at Day 0 in the present study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="262"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="252"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="262"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="252"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="262"/>
                <counts group_id="E3" subjects_affected="197" subjects_at_risk="252"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="254"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="262"/>
                <counts group_id="E3" events="36" subjects_affected="36" subjects_at_risk="252"/>
                <counts group_id="E4" events="19" subjects_affected="19" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Solicited Injection Site Erythema</sub_title>
                <counts group_id="E1" events="135" subjects_affected="135" subjects_at_risk="254"/>
                <counts group_id="E2" events="127" subjects_affected="127" subjects_at_risk="262"/>
                <counts group_id="E3" events="135" subjects_affected="135" subjects_at_risk="252"/>
                <counts group_id="E4" events="63" subjects_affected="63" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Pain</sub_title>
                <counts group_id="E1" events="174" subjects_affected="174" subjects_at_risk="254"/>
                <counts group_id="E2" events="193" subjects_affected="193" subjects_at_risk="262"/>
                <counts group_id="E3" events="177" subjects_affected="177" subjects_at_risk="252"/>
                <counts group_id="E4" events="80" subjects_affected="80" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Solicited Injection Site Swelling</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="254"/>
                <counts group_id="E2" events="69" subjects_affected="69" subjects_at_risk="262"/>
                <counts group_id="E3" events="58" subjects_affected="58" subjects_at_risk="252"/>
                <counts group_id="E4" events="35" subjects_affected="35" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="254"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="262"/>
                <counts group_id="E3" events="28" subjects_affected="28" subjects_at_risk="252"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="254"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="262"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="252"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="95" subjects_affected="95" subjects_at_risk="254"/>
                <counts group_id="E2" events="101" subjects_affected="101" subjects_at_risk="262"/>
                <counts group_id="E3" events="87" subjects_affected="87" subjects_at_risk="252"/>
                <counts group_id="E4" events="42" subjects_affected="42" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="55" subjects_affected="55" subjects_at_risk="254"/>
                <counts group_id="E2" events="66" subjects_affected="66" subjects_at_risk="262"/>
                <counts group_id="E3" events="54" subjects_affected="54" subjects_at_risk="252"/>
                <counts group_id="E4" events="33" subjects_affected="33" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="145" subjects_affected="145" subjects_at_risk="254"/>
                <counts group_id="E2" events="166" subjects_affected="166" subjects_at_risk="262"/>
                <counts group_id="E3" events="166" subjects_affected="166" subjects_at_risk="252"/>
                <counts group_id="E4" events="75" subjects_affected="75" subjects_at_risk="113"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="91" subjects_affected="91" subjects_at_risk="254"/>
                <counts group_id="E2" events="91" subjects_affected="91" subjects_at_risk="262"/>
                <counts group_id="E3" events="87" subjects_affected="87" subjects_at_risk="252"/>
                <counts group_id="E4" events="42" subjects_affected="42" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

